Samarium-153

01/01/2013 - "This review focuses on samarium-153, first defining its radiobiologic and pharmacokinetic properties before describing many clinical trials that support its use as a safe and effective tool in the palliation of patients with bone metastases. "
03/01/2002 - "Bony metastases seen on scintigraphy with samarium-153."
03/01/2001 - "Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis."
01/01/1989 - "Samarium-153 EDTMP therapy of disseminated skeletal metastasis."
04/01/2015 - "Samarium-153 (Sm-153)-EDTMP is routinely used for pain palliation in skeletal metastasis, however most patients report partial response. "

06/01/2005 - "In a randomized phase III trial of two different doses of samarium-153 versus placebo, the complete pain response rate was significantly higher with the higher dose of samarium-153 compared with placebo. "
06/01/2005 - "In a randomized phase III trial of three different doses of samarium-153, the pain responses were similar for all three doses. "
04/01/2009 - "The object of this study was to investigate the use of a minimally invasive technique for treating metastatic tumors of the vertebral body, aimed at relieving pain, preventing further tumor growth, and minimizing the adverse effects of systemic use of samarium-153 ((153)Sm). "
04/01/2015 - "Samarium-153 (Sm-153)-EDTMP is routinely used for pain palliation in skeletal metastasis, however most patients report partial response. "
06/01/2010 - "Samarium-153 treatment of bone pain in patients with metastatic prostate cancer."

03/01/2015 - "Samarium-153 therapy for prostate cancer: the evaluation of urine activity, staff exposure and dose rate from patients."
06/01/2010 - "Samarium-153 treatment of bone pain in patients with metastatic prostate cancer."
01/01/2018 - "First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy."
03/01/2011 - "We completed a Phase I trial to determine the maximum tolerated dose of samarium-153 EDTMP (153Sm) with hormonal therapy (HT) and radiation therapy (RT) in high-risk clinically nonmetastatic prostate cancer. "
03/01/2019 - "We evaluated the samarium-153 (Sm-153) radiopharmaceutical and Au-197 and Sm-153 radiopharmaceutical absorbed dose rate by means of the Monte Carlo technique in prostate cancer. "

05/01/2000 - "Evaluation of samarium-153 for synovectomy in an osteochondral fragment-induced model of synovitis in horses."
02/01/1999 - "Changes in articular synovial lining volume measured by magnetic resonance in a randomized, double-blind, controlled trial of intra-articular samarium-153 particulate hydroxyapatite for chronic knee synovitis."
01/01/1996 - "The clinical outcome and tolerability following treatment with samarium-153 particulate hydroxyapatite was evaluated in patients with persistent rheumatoid knee synovitis. "
01/01/1996 - "Samarium-153 particulate hydroxyapatite knee synovectomy is well tolerated and may be an effective treatment for carefully selected patients with persistent rheumatoid knee synovitis."
01/01/2018 - "This study aimed to evaluate synovectomy with samarium-153 hydroxyapatite (153Sm-HA) in synovitis of the elbows and ankles of hemophilic patients. "

09/01/2016 - "Many studies in recent decades have demonstrated the efficacy of various radiopharmaceuticals, including strontium-89 and samarium-153, for palliation of pain from diffuse skeletal metastases, but no significant benefit in terms of disease progression and overall survival has been shown. "